The epidemiology, treatments and outcomes of patients with hormone receptor positive, human epidermal growth factor receptor 2 negative, node-positive early breast cancer in Taiwan.
Journal
Future oncology (London, England)
Journal Volume
20
Journal Issue
37
ISSN
1744-8301
Date Issued
2024
Author(s)
Tang, Chao-Hsiun
Newson, Rachel Sarah
Chan, Bill Hoi-Fong
Wang, Bruce Cm
Shen, Shih-Pei
Shao, Serena Yu-Ju
Abstract
Estimate patient counts, treatment patterns and outcomes of a subset of patients with early breast cancer (EBC) presenting with hormone receptor positive, human epidermal growth factor receptor 2 negative, node positive features, who are at high-risk of recurrence, in Taiwan. Data from Taiwan's National Health Insurance Research Database and Taiwan Cancer Registry from 1 January 2011 to 31 December 2020 were analyzed. There were 4500 patients with high-risk EBC (10.4% of all patients with EBC) from 2012 to 2018, with an annual average incidence of 643 that increased over time. Five-year progression was 24.8% in patients with high-risk EBC and 8-year survival was low (69.6%). Patients with hormone receptor positive, human epidermal growth factor receptor 2 negative, node positive high-risk EBC clinical features are an increasing high-risk subset of all patients with EBC.
[Box: see text].
Subjects
HER2-
HR+
early breast cancer
health economics
high-risk
node-positive
SDGs
Type
journal article